Jun 14 2010
Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced it has been included on a list of preliminary additions to the Russell Microcap® Index posted by Russell Investments on June 11, 2010 on www.russell.com. These changes are expected to go into effect after the close of trading on Friday, June 25, 2010.
"The preliminary addition of Uroplasty to the Russell Microcap Index could benefit our shareholders by increasing awareness of UPI among institutional investors, and the investment community in general, as we execute our strategies for our Urgent PC® and Macroplastique® product lines," said David Kaysen, President & CEO of Uroplasty.
The Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market and is comprised of the smallest 1,000 companies in the Russell 3000® Index, plus the next smallest 1,000 companies. The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies. The indexes are reconstituted annually.